Association Between Low Plasma Glucose After Oral Glucose Tolerance Test in Pregnancy With Impaired Fetal Growth

Sponsor
Hospital Universitario Dr. Jose E. Gonzalez (Other)
Overall Status
Completed
CT.gov ID
NCT04144595
Collaborator
(none)
300
1
10.9
27.4

Study Details

Study Description

Brief Summary

Objective: To study the association of low maternal plasma glucose in 2 hour 75 g oral glucose tolerance test (OGTT) in women with impaired birth weight and determinate if this result is predictive of low birth weight (<10th percentile according to the INTERGROWTH-21st newborn weight standards for gestational age/sex).

Materials and methods: OGTT at 24-34 week gestation will be performed in pregnant women, the birth weight will be compared between women with low fasting plasma glucose (FPG) (<10th percentile, <65 mg/dL) and normal FPG (≥10th percentile, ≥ 65 mg/dL) also for 1 and 2-hour plasma glucose (1-h PG/2-h PG). Receiver operating characteristic curve analysis will be used to determine the optimal lower OGTT threshold for the prediction of low birth weight.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: 2 hour 75 g Oral glucose tolerance test

Detailed Description

Maternal hypoglycemia has been reported to be linked with low birth weight and poor neonatal outcome. OGTT is performed routinely in pregnancy and hypoglycemia following this screening test is often encountered and the implication of this finding for the fetal growth is unclear.

The aim of study will be determinate the association of low maternal plasma glucose in OGTT in women with impaired birth weight and determinate if this result is predictive of low birth weight (<10th percentile according to the INTERGROWTH-21st newborn weight standards for gestational age/sex).

The study population will consist of patients with singleton pregnancies who will undergo OGTT at 24-34 weeks, have regular medical checkups throughout their entire pregnancy, deliver on or after 25 week gestation and fulfill inclusion criteria.

The birth weight will be compared between women with low fasting plasma glucose (FPG) (<10th percentile, <65 mg/dL*) and normal FPG (≥10th percentile, ≥ 65 mg/dL) also for 1 and 2-hour plasma glucose (1-h PG/2-h PG). Receiver operating characteristic curve analysis will be used to determine the optimal lower OGTT threshold for the prediction of low birth weight.

This study will be performed according to the standards of the Helsinki Declaration and approval was obtained from the ethics and educational issues coordinating committee of our University Hospital.

*Determinated previously in a pilot study

Study Design

Study Type:
Observational
Actual Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Association Between Low Plasma Glucose After Oral Glucose Tolerance Test in Pregnancy With Impaired Fetal Growth
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Oct 28, 2019
Actual Study Completion Date :
Nov 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Low plasma glucose

This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.

Diagnostic Test: 2 hour 75 g Oral glucose tolerance test
In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded

Normal plasma glucose

This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.

Diagnostic Test: 2 hour 75 g Oral glucose tolerance test
In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded

Outcome Measures

Primary Outcome Measures

  1. Birth weight <10th percentile [Newborn birth weight delivered on or after 25 week gestation will be recorded within the first hour after delivery]

    Birth weight <10th percentile according to the INTERGROWTH-21st newborn weight standards for gestational age/sex.

  2. Birthweight <3th percentile [Newborn birth weight delivered on or after 25 week gestation will be recorded within the first hour after delivery]

    Birthweight <3th percentile according to the INTERGROWTH-21st newborn weight standards for gestational age/sex.

  3. Birth weight <2500 g [Newborn birth weight delivered on or after 37 week gestation will be recorded within the first hour after delivery]

    Birth weight <2500 g of newborn delivered on or after 37 week gestation

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women with singleton pregnancy who underwent OGTT at 24-34 weeks and had regular medical checkups throughout their entire pregnancy.

  • Gestational age was determined based on the last menstrual period. If gestational age according to the last menstrual period differed by more than 7 days from that according to ultrasonography at <11 weeks, the latter was used to assign gestational age.

Exclusion Criteria:
  • Inaccurate gestational age

  • OGTT being drawn outside the prescribed window of 24 to 34 weeks gestation.

  • Patients who could not swallow the OGTT solution or vomited afterward were excluded from the study.

  • Patients who were diagnosed with gestational diabetes at any time during their pregnancy were excluded.

  • The following comorbidities or complications that could affect fetal growth also were excluded: cardiac disease, preeclampsia, gestational hypertension, tobacco use, alcohol intake, stimulant drugs use, maternal systemic diseases (e.g., hypertension, pregestational diabetes, autoimmune disease, thrombotic disease, thyroid disease), intrauterine infectious diseases (e.g., cytomegalovirus, rubella, toxoplasmosis, syphilis), major neonatal anomalies or genetic and structural disorders (e.g., trisomy 21, trisomy 18, trisomy 13, congenital heart disease), placental disorders, and umbilical cord abnormalities.

  • Patients with high risk for preeclampsia, intrauterine growth restriction, trisomy 21, trisomy 18 and trisomy 13 in the first trimester screening test.

  • Patients with incomplete or missing data were also excluded.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitario Dr. José Eleuterio González Monterrey Nuevo León Mexico 64460

Sponsors and Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

Investigators

  • Principal Investigator: Flavio Hernández Castro, MD PhD, Obstetrics Department Universidad Autónoma de Nuevo León

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. med Flavio Hernández Castro, Principal investigator, Hospital Universitario Dr. Jose E. Gonzalez
ClinicalTrials.gov Identifier:
NCT04144595
Other Study ID Numbers:
  • GI19-00006
First Posted:
Oct 30, 2019
Last Update Posted:
Jan 13, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. med Flavio Hernández Castro, Principal investigator, Hospital Universitario Dr. Jose E. Gonzalez
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2020